Ch Biotech R&D Co., a leading player in the biotechnology sector, is headquartered in Taiwan (TW) and operates extensively across Asia. Founded in 2002, the company has established itself as a pioneer in biopharmaceutical research and development, focusing on innovative solutions for healthcare challenges. Specialising in the development of biologics and biosimilars, Ch Biotech R&D Co. is recognised for its commitment to quality and scientific excellence. Their core products include advanced therapeutic proteins and monoclonal antibodies, which are distinguished by their efficacy and safety profiles. With a strong market position, Ch Biotech R&D Co. has achieved significant milestones, including successful collaborations with global pharmaceutical firms. Their dedication to research and development continues to drive advancements in the biotechnology industry, making them a trusted name in biopharmaceutical innovation.
How does Ch Biotech R And D Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Ch Biotech R And D Co's score of 21 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2022, Ch Biotech R And D Co, headquartered in Taiwan (TW), reported total carbon emissions of approximately 3,260,880 kg CO2e from Scope 2, 437,910 kg CO2e from Scope 1, and 140,920 kg CO2e from Scope 3. This represents a slight decrease in Scope 1 emissions from 444,390 kg CO2e in 2021, while Scope 2 emissions also decreased from 3,458,040 kg CO2e in the previous year. Despite these reductions, the company has not established specific reduction targets or climate pledges, indicating a potential area for future commitment. The absence of defined reduction initiatives suggests that while Ch Biotech is actively monitoring its emissions, it may benefit from setting more ambitious climate goals to enhance its sustainability profile.
Access structured emissions data, company-specific emission factors, and source documents
2021 | 2022 | |
---|---|---|
Scope 1 | 444,390 | 000,000 |
Scope 2 | 3,458,040 | 0,000,000 |
Scope 3 | 92,920 | 000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ch Biotech R And D Co is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.